HI · As filed with the SEC
Hillenbrand cash flow statement, by fiscal year
The statement as Hillenbrand presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD
| USD | FY2025 Year ended Sep 30, 2025 | FY2024 Year ended Sep 30, 2024 | FY2023 Year ended Sep 30, 2023 | FY2022 Year ended Sep 30, 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Consolidated net income (loss) | 52,100,000 | (202,000,000) | 576,700,000 | 215,200,000 |
| Total income from discontinued operations | 0 | (2,200,000) | (462,600,000) | — |
| Adjustments to reconcile income (loss) from continuing operations to cash provided by operating activities: | ||||
| Depreciation and amortization | 138,500,000 | 158,000,000 | 125,600,000 | 108,200,000 |
| Impairment charges | 83,500,000 | 265,000,000 | 0 | 0 |
| Gain on sale of property, plant, and equipment | 0 | (36,000,000) | — | — |
| Gain on equity method investments | (74,600,000) | — | — | — |
| Pension settlement (gain) charges | 0 | 35,200,000 | — | — |
| Deferred income taxes | (131,100,000) | (39,600,000) | (5,600,000) | 23,500,000 |
| Amortization of deferred financing costs | 7,700,000 | 6,200,000 | 3,800,000 | 3,600,000 |
| Share-based compensation | 17,900,000 | 20,300,000 | 18,800,000 | 21,300,000 |
| Settlement of Milacron share-based equity awards | — | — | — | 0 |
| Loss on divestiture | 57,200,000 | 0 | 0 | 3,100,000 |
| Trade receivables and receivables from long-term manufacturing contracts | (1,600,000) | (5,900,000) | (30,800,000) | (115,900,000) |
| Inventories, net | 33,900,000 | 83,100,000 | 57,200,000 | (125,500,000) |
| Prepaid expenses and other current assets | (17,300,000) | (17,800,000) | 19,500,000 | (23,200,000) |
| Trade accounts payable | (25,300,000) | (17,800,000) | (14,700,000) | 105,500,000 |
| Liabilities from long-term manufacturing contracts and advances, accrued compensation, and other current liabilities | (83,000,000) | (70,900,000) | (95,800,000) | (14,100,000) |
| Income taxes payable | 6,100,000 | (6,600,000) | 29,400,000 | 7,900,000 |
| Accrued pension and postretirement | — | — | (9,400,000) | (10,500,000) |
| Defined benefit plan expense | — | — | — | 1,700,000 |
| Accrued pension and postretirement | (3,300,000) | 20,300,000 | — | — |
| Other, net | (4,500,000) | 2,000,000 | (5,100,000) | (9,700,000) |
| Net cash provided by operating activities | — | — | — | 191,100,000 |
| Net cash provided by operating activities from continuing operations | 56,200,000 | 191,300,000 | 207,000,000 | — |
| Investing activities from continuing operations | ||||
| Capital expenditures | (38,300,000) | (54,200,000) | (69,300,000) | (50,300,000) |
| Proceeds from sales of property, plant, and equipment | 2,100,000 | 56,300,000 | 800,000 | 2,000,000 |
| Acquisitions of businesses, net of cash acquired | 0 | (900,000) | (1,350,900,000) | (90,600,000) |
| Proceeds from sale of equity method investment | 114,700,000 | — | — | — |
| Proceeds from divestiture, net of cash divested | 83,900,000 | 0 | 696,700,000 | (4,500,000) |
| Cross-currency swap settlement | 9,100,000 | — | — | — |
| Proceeds from Sale and Collection of Receivables | 20,800,000 | 25,600,000 | — | — |
| Other, net | 400,000 | 0 | 400,000 | — |
| Net cash (used in) provided by investing activities | — | — | — | (143,400,000) |
| Net cash provided by (used in) investing activities from continuing operations | 192,700,000 | 26,800,000 | (722,300,000) | — |
| Financing activities from continuing operations | ||||
| Proceeds from long-term debt, net of discount | 468,500,000 | 500,000,000 | 401,400,000 | 0 |
| Repayments of long-term debt | (579,000,000) | (420,100,000) | (107,500,000) | 0 |
| Proceeds from revolving credit facilities | 388,500,000 | 895,800,000 | 1,467,400,000 | 83,000,000 |
| Repayments on revolving credit facilities | (475,400,000) | (1,124,200,000) | (1,009,400,000) | (74,300,000) |
| Payment of deferred financing costs | (7,400,000) | (7,400,000) | (3,300,000) | (3,700,000) |
| Payment of dividends on common stock | (63,400,000) | (62,500,000) | (61,300,000) | (62,000,000) |
| Repurchases of common stock | — | 0 | 0 | (203,900,000) |
| Proceeds from stock option exercises and other | 1,000,000 | 2,400,000 | 21,000,000 | 25,300,000 |
| Payments for employee taxes on net settlement equity awards | (3,400,000) | (7,000,000) | (12,700,000) | (7,000,000) |
| Other, net | (8,800,000) | (4,100,000) | (2,200,000) | (1,600,000) |
| Net cash (used in) provided by financing activities from continuing operations | (279,400,000) | (227,100,000) | 693,400,000 | (244,200,000) |
| Effect of exchange rate changes on cash and cash equivalents | — | — | — | (16,800,000) |
| Cash (used in) provided by continuing operations | (30,500,000) | (9,000,000) | 178,100,000 | — |
| Cash Provided by (Used in) Operating Activity, Discontinued Operation | 0 | (23,300,000) | (136,800,000) | — |
| Cash Provided by (Used in) Investing Activity, Discontinued Operation | 0 | 0 | (7,600,000) | — |
| Total cash used in discontinued operations | 0 | (23,300,000) | (144,400,000) | — |
| Effect of exchange rates on cash and cash equivalents | (6,000,000) | 10,000,000 | (21,100,000) | — |
| Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation, Total | (36,500,000) | (22,300,000) | 12,600,000 | (213,300,000) |
| At Beginning of Period | 227,900,000 | 250,200,000 | 237,600,000 | 450,900,000 |
| At End of Period | 191,400,000 | 227,900,000 | 250,200,000 | 237,600,000 |
| Cash paid for interest | 89,500,000 | 123,400,000 | 80,600,000 | 62,600,000 |
| Cash paid for income taxes | 67,900,000 | 115,800,000 | 238,600,000 | 71,500,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.